Neumora Therapeutics Inc
NASDAQ:NMRA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.6151
11.06
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Neumora Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
N
|
Neumora Therapeutics Inc
NASDAQ:NMRA
|
288.3m USD | N/A | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
44%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
499.4B USD |
27%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
262B CHF |
34%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.4B GBP |
24%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
211.1B CHF |
33%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
265.9B USD |
38%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
42%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
212.8B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.2B USD |
29%
|
Neumora Therapeutics Inc
Glance View
In the bustling world of biopharmaceuticals, Neumora Therapeutics Inc. carves a unique path through the intricacies of neuroscience, specializing in precision medicines for brain diseases. Founded on the convergence of a deep understanding of neurological disorders and cutting-edge data science, Neumora's mission centers around developing targeted therapies that offer hope and clarity to those grappling with complex mental health issues. The company harnesses an impressive integration of human data insights, machine learning tools, and novel biomarker technologies to identify and validate new therapeutic targets. This strategic approach allows Neumora to streamline the drug discovery and development process, ensuring a more precise alignment between therapeutic interventions and the specific needs of patient subtypes. Monetization for Neumora emerges through strategic collaborations, partnerships, and potential commercial sales of its approved therapies. By forming alliances with research institutions and pharmaceutical giants, the company not only enhances its R&D capabilities but also secures vital funding to propel its clinical programs. Furthermore, Neumora's business model may encompass licensing deals, allowing it to monetize its technology and intellectual properties, including proprietary biomarkers and AI-driven discovery platforms. As drug candidates advance through clinical trials and towards regulatory approval, Neumora positions itself to capture market share by addressing unmet needs in the neurology therapeutic landscape, offering innovative solutions in an industry ripe for disruption.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Neumora Therapeutics Inc's most recent financial statements, the company has Operating Margin of 0%.